Product Description

Sotorasib is an acrylamide derived KRAS inhibitor developed by Amgen and is currently undergoing clinical trials for solid tumors with KRAS G12C mutations. This mutation makes up >50% of all KRAS mutations. It is the first experimental KRAS inhibitor. The drug [MRTX849] is also currently being developed and has the same target.